Watt FE, et al. - Via a phase 2a, double-blind, placebo- and naproxen-controlled, double-dummy, parallel-group study of 215 with knee OA (impacts ∼27 million people in the US and contributes to the current raised rates of knee arthroplasty), researchers examined the Tropomyosin-related kinase A inhibitor, ASP7962, for treatment of painful knee OA. Between ASP7962 and placebo, no important variation was noted in change from baseline to Week 4 in Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain subscale score and a notable variation was recognized between naproxen and placebo. No variations were discovered between ASP7962 and placebo in change from baseline in any WOMAC subscale score and statistically important variances were seen between naproxen and placebo. ASP7962 was safe and well-tolerated. Thus, in people with painful knee OA, a 4-week treatment with ASP7962 (100 mg BID) did not improve pain or physical function.